These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 27405747

  • 21. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M.
    J Clin Oncol; 2014 Mar 01; 32(7):634-40. PubMed ID: 24449241
    [Abstract] [Full Text] [Related]

  • 22. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
    Butrym A, Rybka J, Łacina P, Gębura K, Frontkiewicz D, Bogunia-Kubik K, Mazur G.
    Leuk Res; 2015 Dec 01; 39(12):1462-6. PubMed ID: 26521987
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.
    Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ.
    Int J Cancer; 2012 Sep 01; 131(5):E636-42. PubMed ID: 22139971
    [Abstract] [Full Text] [Related]

  • 25. TNF-α, TNF-β and IL-10 gene polymorphism and association with oral lichen planus risk in Saudi patients.
    Al-Mohaya MA, Al-Harthi F, Arfin M, Al-Asmari A.
    J Appl Oral Sci; 2015 Sep 01; 23(3):295-301. PubMed ID: 26221924
    [Abstract] [Full Text] [Related]

  • 26. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H, Meng H, Wang J, Lou Y, Zhou Y, Lin P, Li F, Liu L, Xu H, Yang M, Jin J.
    Front Med; 2020 Jun 01; 14(3):327-334. PubMed ID: 31784918
    [Abstract] [Full Text] [Related]

  • 27. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.
    Almasi M, Sevcikova S, Slaby O, Kaisarova P, Maisnar V, Penka M, Pika T, Pour L, Radocha J, Scudla V, Svachova H, Hajek R.
    Clin Lymphoma Myeloma Leuk; 2011 Oct 01; 11(5):414-20. PubMed ID: 21859556
    [Abstract] [Full Text] [Related]

  • 28. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
    Wu S, Zheng C, Chen S, Cai X, Shi Y, Lin B, Chen Y.
    Biomed Res Int; 2015 Oct 01; 2015():927105. PubMed ID: 26425561
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M, Michiels A, Doyen C, Kentos A, Van Droogenbroeck J, Offner F, Bries G, Demuynck H, Vekemans MC, Meuleman N, Mineur PO, Ravoet C, Depryck B, Van de Velde A, Pierre P, Wu KL, Schots R.
    Acta Clin Belg; 2011 Oct 01; 66(5):371-5. PubMed ID: 22145272
    [Abstract] [Full Text] [Related]

  • 31. [Relationship between gene polymorphism at rs2228055 locus in the exon region of interleukin-10 receptor A and susceptibility to food allergy in children].
    Sun JB, Li ZL.
    Zhonghua Er Ke Za Zhi; 2020 Jul 02; 58(7):559-563. PubMed ID: 32605339
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
    Blommestein HM, Verelst SG, de Groot S, Huijgens PC, Sonneveld P, Uyl-de Groot CA.
    Eur J Haematol; 2016 Feb 02; 96(2):198-208. PubMed ID: 25892333
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
    Tazawa S, Shiozawa E, Homma M, Arai N, Kabasawa N, Kawaguchi Y, Fujiwara S, Okino K, Kobayashi K, Yamochi T, Tate G, Nakamaki T, Takimoto M.
    J Clin Exp Hematop; 2015 Feb 02; 55(3):121-6. PubMed ID: 26763359
    [Abstract] [Full Text] [Related]

  • 38. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
    García-Sanz R, Corchete LA, Alcoceba M, Chillon MC, Jiménez C, Prieto I, García-Álvarez M, Puig N, Rapado I, Barrio S, Oriol A, Blanchard MJ, de la Rubia J, Martínez R, Lahuerta JJ, González Díaz M, Mateos MV, San Miguel JF, Martínez-López J, Sarasquete ME, GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.
    Hematol Oncol; 2017 Dec 02; 35(4):746-751. PubMed ID: 27605156
    [Abstract] [Full Text] [Related]

  • 39. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF.
    Lancet Oncol; 2010 Oct 02; 11(10):934-41. PubMed ID: 20739218
    [Abstract] [Full Text] [Related]

  • 40. Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
    Mian M, Tinelli M, DE March E, Turri G, Meneghini V, Pescosta N, Berno T, Marabese A, Mondello P, Patriarca F, Pizzolo G, Semenzato G, Cortelazzo S, Zambello R.
    Anticancer Res; 2016 Mar 02; 36(3):1059-65. PubMed ID: 26976998
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.